Pharmacology By Farrukh Jabbar Pdf - Compact

If you’re looking for a draft guide to use alongside the book, here’s a structured template you can complete as you study:

3. Cardiovascular Drugs

• Diuretics – Loop (Furosemide), Thiazide (HCTZ), K⁺-sparing (Spironolactone)
• ACE inhibitors (Lisinopril) → ↓ Ang II → vasodilation, ↓ aldosterone
• Calcium channel blockers – Dihydropyridines (Amlodipine) = vasodilation; Non-DHP (Verapamil) = ↓ HR
• Antiarrhythmics – Vaughan-Williams classification (memorize Class I–IV)

How educators and clinicians can use the book

• As a concise handout for lectures or bedside teaching.
• Quick reference during clinical rounds for common drug regimens.
• Source of multiple-choice style revision questions and short-answer prompts.

Hematology and oncology basics

• Chemotherapy principles: cell-cycle specific vs nonspecific agents, common toxicities (myelosuppression, mucositis).
• Targeted therapies and immunotherapies: basic mechanisms (tyrosine kinase inhibitors, monoclonal antibodies).
• Supportive oncology pharmacology: antiemetics, growth factors, tumor lysis prevention.

Endocrine and metabolic drugs

• Insulins and oral hypoglycemics: classification, onset/duration, and hypoglycemia risk.
• Thyroid and antithyroid agents.
• Corticosteroids: indications, dosing concepts, and adverse effects (HPA axis suppression).
• Osteoporosis drugs: bisphosphonates, SERMs, denosumab.

6. Chemotherapy

• Methotrexate – Dihydrofolate reductase inhibitor
• Doxorubicin – Topoisomerase II inhibitor, cardiotoxic
• Cyclophosphamide – Alkylating agent → hemorrhagic cystitis

Pharmacokinetics and pharmacodynamics

• ADME: absorption (bioavailability, first-pass effect), distribution (volume of distribution, protein binding), metabolism (phase I/II reactions, CYP450 isoenzymes), excretion (renal clearance).
• Key parameters: half-life, steady state, clearance, loading vs maintenance dosing.
• Receptor theory: agonists, partial agonists, antagonists (competitive/noncompetitive), inverse agonists.
• Dose–response curves: EC50, efficacy vs potency.
• Therapeutic index and safety margins.